Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates
Completed · Phase 1
Conditions studied: Sepsis
In brief
This is a phase I open label multi-dose study to investigate the pharmacokinetics and safety of piperacillin-tazobactam in infants \< 61 days of age with suspected sepsis. There will be four cohorts of 8 infants each: 1. \< 32 weeks gestational age (GA) and \< 14 days postnatal age (PNA) 2. \< 32 weeks gestational age and \>=14 days postnatal age 3. \>=32 weeks gestational age and \< 14 days postnatal age 4. \>=32 weeks gestational age and \>=14 days postnatal age. The study requires administration of 6 doses of study drug along with other antimicrobials per standard of care followed by 1 week of safety monitoring. Four 200 µL pK samples will be obtained at steady state. The risks are reasonable vs. the benefits and have been minimized appropriately. There may be benefit to the subjects (administration of broad spectrum empirical antimicrobial therapy), and information from the study may benefit a large number of other infants in whom the drug is currently being administered despite the lack of PK data in this population.
Key facts
- Study ID
- NCT00873327
- Run by
- Phillip Brian Smith
- People needed
- 32
- Starts
- 2009-10-01
- Expected to finish
- 2010-07-01
- Last updated by the study team
- 2018-10-03
Who can join
Age: any, up to 0. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Written permission from parent or legal guardian
- < 61 days of age
- Likely to survive beyond the first 48 hours after enrollment
- Sufficient intravascular access (either peripheral or central) to receive study drug.
- AND ONE OF THE FOLLOWING
- Suspected systemic infection
- Receiving piperacillin-tazobactam as part of standard of care
You may not qualify if…
- History of allergic reactions to any penicillin, cephalosporins, or beta-lactamase inhibitors
- Urine output < 0.5 mL/hr/kg over the prior 24 hours
- Serum creatinine > 1.2 mg/dL
- Any condition which would make the subject or the caregiver, in the opinion of the investigator, unsuitable for the study
Where it is running
- Indiana University School of Medicine — Indianapolis, Indiana, United States
- Wesley Medical Center — Wichita, Kansas, United States
- Children's Mercy Hospital — Kansas City, Missouri, United States
- Duke University Medical Center — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.